Market Overview - On January 26, 2026, the North Exchange 50 index fell by 1.45%[1] - The average market capitalization of the North Exchange component stocks is 3.274 billion, with a trading volume of 32.814 billion, a decrease of 0.321 billion from the previous trading day[13] Capital Market News - The State Administration for Market Regulation reported that the Chinese corporate credit index for Q4 2025 was 162.18, reflecting a slight increase of 0.52 points from Q3 2025, indicating a stable and improving credit environment[6] - The People's Bank of China conducted a 150.5 billion reverse repurchase operation, resulting in a net withdrawal of 207.8 billion from the open market[8] Industry News - The Ministry of Commerce announced plans to optimize the implementation of the old-for-new policy for consumer goods, aiming to boost consumption of durable goods such as home appliances and automobiles in 2026[9] - Tianjin aims to establish a national brain-computer interface technology innovation center, focusing on key technological breakthroughs and enhancing local innovation capabilities[11] Company Announcements - Dayu Biological expects a net loss of 26 to 30 million for 2025, a decline of 25.3% to 8.59% compared to the previous year due to industry challenges[26] - Shibi Bai forecasts a net profit of 50 to 60 million for 2025, a significant turnaround from a loss of 3.675 million the previous year, driven by increased demand for metal composite materials[27] - Oufu Egg Industry anticipates a net profit of 80 to 92 million for 2025, a year-on-year increase of 75.44% to 101.75% due to expanded production capacity and improved market conditions[28]

Group 1 - The core viewpoint of the news highlights the significant growth and potential of China's innovative pharmaceuticals, particularly in the context of international expansion and investment confidence [1] - The year 2025 is marked as a pivotal year for China's innovative pharmaceuticals, with total outbound licensing transaction amounts reaching $135.655 billion and a record 157 transactions [1] - The continuous successful BD transactions validate the global competitiveness of Chinese innovative drugs, supporting long-term investment confidence [1] Group 2 - The small nucleic acid drug sector is making notable progress, with leading companies accelerating their development in new target discovery and treatment convenience, attracting increased attention [1] - The GLP-1 sector is expected to have long-term market potential following the establishment of a new pricing system [1] - Domestic companies are actively pursuing relevant targets in the oral autoimmune drug space, indicating significant value [1] Group 3 - The brain-computer interface technology is at a critical juncture for industrialization, with substantial advancements in policy support, device approval, insurance coverage, and clinical applications [1] - Developments in radiation therapy equipment technology are creating new market opportunities worth billions [1] Group 4 - The ETF Guotai (589720) tracks the innovative drug index (950161), which includes listed companies engaged in innovative drug research and development, covering various fields such as biopharmaceuticals, chemical drugs, and traditional Chinese medicine [2] - The index reflects the overall performance of listed companies in China's pharmaceutical innovation sector [2]

Group 1: Industry Overview and Challenges - The domestic ophthalmology medical service industry is gradually emerging from an adjustment period, with increasing demand driven by national policies and a large population base [1][2] - The low penetration rate of various sub-specialties in ophthalmology, coupled with high myopia rates among youth and aging-related eye diseases, presents significant growth opportunities [1][2] Group 2: Business Strategy and Development Plans - The company has initiated a "three-year攻坚" plan focusing on solidifying its foundation, enhancing operational efficiency, and promoting sustainable high-quality development [3][4] - Key strategies include deepening internal growth, advancing technological innovation and digital transformation, consolidating talent and research advantages, and adapting to market and policy changes [3][4][5] Group 3: International Expansion - The company has established a presence in Europe, Southeast Asia, and the United States, with overseas business contributing approximately 13% to total revenue [6] - The international strategy emphasizes adapting to local market conditions and regulatory environments while leveraging domestic expertise in ophthalmology [6] Group 4: Technological Innovation and Research - The company is exploring the application of cutting-edge technologies in visual reconstruction and eye care through strategic partnerships, although these initiatives are still in early stages and unlikely to impact short-term performance [7]

Investment Rating - The report maintains a strong recommendation for the gaming sector, particularly highlighting the performance of "Heart Town" in international markets [1][2]. Core Insights - The media industry has seen a 3.34% increase over the past week, ranking third among all sectors, and a 16.92% increase year-to-date, leading all sectors [1]. - The report emphasizes the potential of key companies in the gaming sector, with several titles showing significant performance improvements in international markets [1]. - The report identifies opportunities in the overseas and female-oriented gaming markets, projecting a 14.08% year-on-year increase in sales revenue for the Chinese market in the first half of 2025, reaching 168 billion yuan [1]. - AI applications are expected to continue influencing the gaming industry positively, enhancing production efficiency and creativity [1]. Summary by Sections Market Performance - The media sector's overall performance shows a 3.34% increase from January 12 to January 18, with the media index outperforming the Shanghai Composite Index [10][1]. - Key companies in the media sector have shown varied performance, with notable increases in stocks like Liou Co. and People's Daily [13]. Gaming Sector Highlights - "Heart Town" has topped the free charts in over 50 regions globally since its international launch on January 8, 2026, indicating strong overseas marketing capabilities [2]. - The gaming market in China is projected to reach 168 billion yuan in sales revenue in the first half of 2025, with a user base of 679 million [1]. - The report highlights the significant growth potential in the female gaming market, with a projected market size of 8 billion yuan in 2024, growing at a rate of 124.1% [1]. Company Performance - Key companies such as Century Huatong and Giant Network are expected to see significant revenue growth from new game launches and international expansions [1]. - The report notes that AI technology is enhancing game production and marketing efficiency, with companies like 37 Interactive Entertainment and Century Huatong investing in related technologies [1].

本报讯 1月20日，由海南大学作为核心依托和牵头单位筹建的海南省脑空间信息学与脑机接口技术创新 中心（以下简称"技术创新中心"）揭牌仪式在海南大学生物医学工程学院举行。同期，海南大学与海口 市人民医院、三亚中心医院、海南省第二人民医院共建脑机接口临床与转化基地揭牌。 揭牌仪式上，中国科学院院士、海南大学校长、技术创新中心主任骆清铭表示，脑机接口技术已经被列 入国家重点发展产业，在海南省科学技术厅会同相关部门的积极推动下，该技术创新中心应运而生。中 心建设聚焦创新引领与需求牵引、自主可控与开放合作、产学研医与跨界融合等原则，通过构建基础理 论突破平台、临床应用平台、产业创新平台及管理与转化平台四大核心平台，聚焦脑空间信息学、脑机 接口专用芯片、神经电极等"卡脖子"技术与前沿方向开展集中攻关，吸纳脑空间信息学、脑机芯片神经 工程等多个专业团队进行技术攻坚创新，联合脑专科医院及相关科技企业等共建单位合作发展，为脑机 接口领域发展提供全方位支撑。通讯员 王一钦 记者 王小武 ...

Core Insights - The Ministry of Industry and Information Technology (MIIT) aims to promote deep integration of technological and industrial innovation by 2025, focusing on key core technology breakthroughs and major equipment development [1][6] - Significant advancements in various sectors include a 26.7% increase in the value added of integrated circuits and a 28% rise in industrial robot production, with new energy vehicle sales reaching 16.49 million units, up 28.2% year-on-year [1][10] - The 6G technology research has completed its first phase, resulting in over 300 key technology reserves, with the second phase of testing recently initiated [3][8] Industry Growth - Emerging sectors such as aerospace and equipment manufacturing are experiencing double-digit investment growth, indicating a robust investment trend in new industries [1][10] - High-quality innovative results are emerging, with advancements in perovskite materials, permanent magnet materials, and power batteries reaching international standards [5][10] Future Initiatives - The MIIT plans to implement actions to develop and strengthen emerging industries, create national demonstration bases for new industries, and support local governments in establishing future industry pilot zones [6][10] - The government will increase investment in strategic technology projects and promote large-scale applications of new technologies and products in manufacturing [6][10]

Group 1 - The core viewpoint of the article highlights the positive developments in the pharmaceutical industry, particularly in the innovative drug sector, driven by multiple favorable factors such as increased funding, industry conferences, and performance forecasts [1] - The Cathay Innovation Drug ETF (589720) has seen a net inflow of over 130 million yuan for five consecutive days, indicating strong investor interest in the sector [1] - The industry is benefiting from positive clinical data for small nucleic acid drugs and increased collaborations, which are expected to enhance the outlook for innovative drugs [1] Group 2 - Neuralink plans to start mass production in 2026, aiming for safer surgical operations in the brain-computer interface technology sector [1] - The AI and pharmaceutical fields are evolving, with OpenAI launching ChatGPTHealth and several domestic AI drug companies exploring new business models [1] - The domestic CRO (Contract Research Organization) sector is experiencing a significant increase in demand, with new orders accelerating on a month-over-month basis [1] Group 3 - The Cathay Innovation Drug ETF focuses on innovative drug companies listed on the Sci-Tech Innovation Board, tracking a representative index of 30 high-quality companies [1] - During the market rebound period from September 24, 2024, to October 31, 2025, the Sci-Tech Innovation Drug Index and the Hang Seng Hong Kong Stock Connect Innovation Drug Index are expected to rise by 143.70% and 135.34%, respectively [1] - The Sci-Tech Innovation Drug Index may provide better exposure to the resilience of the Sci-Tech Innovation Board when market risk appetite increases [1]

Core Insights - The article discusses the establishment of a brain-computer interface (BCI) outpatient clinic at Wuxi People's Hospital, aimed at treating refractory neurological and psychiatric disorders, with a focus on multidisciplinary collaboration for patient care [1][10]. Group 1: Outpatient Services - The BCI outpatient clinic offers a multidisciplinary team (MDT) approach, where specialists from various departments collaborate to diagnose and propose treatment plans for patients, as demonstrated by a case of a patient suspected of early Parkinson's disease [1][3]. - The clinic utilizes advanced diagnostic techniques, including imaging studies and expert consultations, to assess patients' conditions and recommend treatment options [3]. Group 2: Rehabilitation Facilities - A dedicated clinical research ward for BCI has been established, where patients with conditions like stroke-related paralysis can engage in rehabilitation exercises using BCI technology, which allows for passive movement through visual cues [5][10]. - The rehabilitation process involves capturing brain signals through electrodes and translating them into actions, enabling patients to perform movements or swallowing exercises with the aid of technology [5][10]. Group 3: Comprehensive Treatment Approach - The BCI system encompasses a full treatment chain, including assessment, diagnosis, treatment, and rehabilitation, integrating BCI and neuro-regulation technologies to provide a one-stop precision treatment platform for patients with conditions such as stroke, spinal cord injury, Parkinson's disease, and Alzheimer's disease [10][12]. - The hospital aims to lead in the development of BCI technologies, focusing on both invasive and non-invasive methods, and plans to establish academic organizations and regional alliances to foster collaborative innovation in the field [12]. Group 4: Future Developments - The hospital's neurology department has been conducting deep brain stimulation (DBS) surgeries since 2017 and is advancing in open-loop BCI technology, accumulating significant data and experience in neural signal collection and response regulation [12]. - The BCI technology is expected to revolutionize the fields of neuro-regulation and rehabilitation, with potential future applications in cognitive function restoration and speech communication rehabilitation [12].

Summary of Conference Call for Kefu Medical and Lizhi Intelligent Industry and Company Overview - The conference call primarily discusses the collaboration between Kefu Medical and Lizhi Intelligent in the non-embedded brain-machine rehabilitation sector, aiming to integrate their strengths for business synergy in both B-end (hospitals) and C-end (consumers) markets [2][4]. Key Points and Arguments Collaboration and Market Strategy - Kefu Medical and Lizhi Intelligent are working together to enhance product value by combining brain-controlled rehabilitation robots with existing products, such as integrating sleep devices with ventilators [2][10]. - The partnership aims to leverage Kefu Medical's market data to iterate AI algorithms, creating a closed-loop system that enhances product profitability and brand reputation [2][11]. Technological Advancements - Lizhi Intelligent has developed a comprehensive technology chain in brain-machine interface technology, including sensor data acquisition, algorithm decoding, and execution control, which has been successfully applied in rehabilitation robots [6][8]. - The focus is on non-invasive brain-machine interface technology, which has broad application prospects in home rehabilitation, particularly for sleep management, pain management, and Parkinson's disease [5][16]. Market Demand and Policy Support - The aging population in China, which reached a rate of 22% in 2025, is driving the demand for home rehabilitation solutions [2][11]. - There is a high clinical demand for brain-machine interface products, with over 500 million yuan in orders already secured [7][14]. - At least 15 provinces in China have introduced supportive policies for the brain-machine interface industry, enhancing institutional purchasing enthusiasm [15][18]. Financial and Investment Insights - Kefu Medical has made significant investments in Lizhi Intelligent, with plans to gradually increase its shareholding to achieve business synergy [4][22]. - The company is also collaborating with Philips, with a new team established to develop a series of products expected to launch by the end of Q2 2026 [24][25]. Future Outlook - The brain-machine interface industry is in its early stages, with a projected development window of 5 to 10 years, driven by technological advancements and the growing demand from an aging population [18]. - Kefu Medical is focused on expanding its product lines and enhancing its international capabilities, with plans for an IPO in Hong Kong nearing completion [27][28]. Additional Important Content - Lizhi Intelligent's collaboration with South China University of Technology aims to foster talent and technology integration, enhancing product development and iteration [12]. - The company is also exploring invasive brain-machine interface technologies, although these are still in the research phase [12][16]. - The competitive advantage lies in providing practical, clinically applicable solutions that meet diverse medical needs, ensuring revenue generation through genuine partnerships rather than free distribution [19].

Core Insights - The successful implementation of non-invasive brain-computer interface (BCI) technology at the First Affiliated Hospital of Bengbu Medical College has provided new rehabilitation hope for acute stroke patients with hemiplegia [2][3] - This innovative treatment allows for early neural repair interventions within 72 hours of stroke onset, addressing the limitations of traditional thrombolysis and thrombectomy methods [2][3] Group 1: Treatment Details - The first patient treated was relatively young and exhibited left-sided hemiplegia, with noticeable instability despite being able to walk and raise their hand [2] - The treatment involved a non-invasive BCI approach, which was applied alongside conventional medication, leading to significant improvements in the patient's motor functions [3] - The BCI technology utilized high-precision MRI to create a personalized brain model, allowing for accurate targeting of the damaged areas [3] Group 2: BCI Technology Overview - BCI technology establishes a new communication channel between the brain and external devices, enabling direct interaction and control [4] - It can be categorized into invasive, semi-invasive, and non-invasive types, with non-invasive BCI being favored for its safety and broad applicability [5] Group 3: Market Potential and Future Applications - There is a large population of patients in China suffering from severe neurological disorders, including over 28 million stroke patients, which highlights the potential market for BCI technology [5] - The ongoing advancements in neuroscience, materials science, microelectronics, and artificial intelligence are expected to enhance the application prospects of BCI technology in various medical fields [5] - The non-invasive BCI approach is seen as a safer and more accessible option, likely to integrate into everyday life for a broader audience [6] Group 4: Clinical Development - The hospital is initiating treatment for a second batch of acute stroke patients and is actively exploring BCI applications in other neurological diseases such as Alzheimer's and Parkinson's [6]